Cargando…

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer

SIMPLE SUMMARY: Cancer treatments have significantly changed with the introduction of immunotherapy. Recently, the development of new agents that harness the redirection of T-cells against cancer is rapidly emerging in multiple tumor types. Since bispecific T-cell engager (BiTE) therapies have demon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simão, Diana C., Zarrabi, Kevin K., Mendes, José L., Luz, Ricardo, Garcia, Jorge A., Kelly, William K., Barata, Pedro C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001031/ https://www.ncbi.nlm.nih.gov/pubmed/36900202 http://dx.doi.org/10.3390/cancers15051412

Ejemplares similares

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
por: Ribera, Jose-Maria, et al.
Publicado: (2020)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Bispecific protein targets prostate cancer
por: Burgess, Antony W.
Publicado: (2017)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
por: Kühl, Lennart, et al.
Publicado: (2023)

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy
por: Penny, Hweixian Leong, et al.
Publicado: (2023)

Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors
por: Wei, Min, et al.
Publicado: (2022)

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
por: Stadler, Christiane R., et al.
Publicado: (2015)

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
por: Lund, Maria E., et al.
Publicado: (2020)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
por: Morcos, Peter N., et al.
Publicado: (2020)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
por: Antonarelli, Gabriele, et al.
Publicado: (2021)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
por: Liguori, Luigi, et al.
Publicado: (2022)

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
por: Carrara, Stefania C., et al.
Publicado: (2022)

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice
por: Liu, X, et al.
Publicado: (2016)

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
por: Bi, Yanyu, et al.
Publicado: (2017)

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
por: Heidbuechel, Johannes P. W., et al.
Publicado: (2021)

Development of a bispecific immune engager using a recombinant malaria protein
por: Nordmaj, Mie A., et al.
Publicado: (2021)

Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma
por: Hua, Gwen, et al.
Publicado: (2022)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3s8pceiqlit03081n31bnir93a